Welcome to our dedicated page for Coya Therapeutics news (Ticker: COYA), a resource for investors and traders seeking the latest updates and insights on Coya Therapeutics stock.
Coya Therapeutics, Inc. (NASDAQ: COYA) is a clinical-stage biotechnology company headquartered in Houston, Texas, with news flow centered on its regulatory T cell (Treg)–focused pipeline for neurodegenerative and inflammation-driven diseases. Company updates frequently highlight progress with COYA 302, an investigational proprietary biologic combination of low-dose interleukin-2 (LD IL-2) and CTLA-4 Ig, and COYA 303, an investigational combination of LD IL-2 and a GLP-1 receptor agonist.
Investors following COYA news can expect regular coverage of clinical trial milestones, including the Phase 2 ALSTARS Trial of COYA 302 in amyotrophic lateral sclerosis (ALS). Coya has announced key events such as FDA acceptance of its IND for COYA 302 in ALS, Health Canada’s acceptance of a Clinical Trial Application, initiation and dosing of patients in the ALSTARS Trial, and milestone payments received under its Development and License Agreement with Dr. Reddy’s Laboratories Ltd.
News items also describe regulatory developments for frontotemporal dementia (FTD), including FDA acceptance of an IND for COYA 302 in FTD and results from an investigator-initiated open-label study of low-dose IL-2 and CTLA4-Ig in FTD patients. Additional releases cover preclinical data for COYA 303 in an in vivo model of systemic and neurologic inflammation, corporate financing activities such as an upsized public offering of common stock, and quarterly financial results and corporate updates.
This COYA news page aggregates these disclosures so readers can review clinical, regulatory, scientific, and financing announcements in one place. For those tracking Treg-based approaches to ALS, FTD, Alzheimer’s disease, and related conditions, the news stream provides direct access to Coya’s reported data, trial status updates, and key corporate events over time.
Coya Therapeutics (NASDAQ: COYA) announced results from a proof-of-concept clinical study for its investigational biologic combination, COYA 302, aimed at treating Amyotrophic Lateral Sclerosis (ALS). Conducted over 12 months, the study evaluated safety, tolerability, regulatory T cell function, serum biomarkers, and clinical performance using the ALSFRS-R scale. The dual-mechanism therapy combines low-dose Interleukin-2 and a fusion protein to enhance anti-inflammatory effects while reducing pro-inflammatory responses. Dr. Stanley Appel presented these findings at the 2023 MDA Clinical & Scientific Conference in Dallas, Texas, from March 19 to March 22.
Coya Therapeutics, Inc. (NASDAQ: COYA) has expanded its license agreement with ARScience Biotherapeutics, Inc. to include exclusive worldwide rights for COYA 301, an immunomodulatory cytokine aimed at treating autoimmune and neurodegenerative diseases. This expansion allows Coya to develop COYA 301 as a monotherapy for serious autoimmune diseases in addition to previous rights for neurodegenerative conditions. Coya’s CEO, Howard Berman, emphasizes the potential to address inflammation in a broader patient population. The collaboration aims to advance treatments for conditions characterized by Treg dysfunction and sustained inflammation, leveraging Coya's expertise in Treg-enhancing therapies.
Coya Therapeutics, Inc. (NASDAQ: COYA) has announced plans to present proof-of-concept clinical data from two academic studies on its investigational therapies for Alzheimer’s disease (COYA 301) and Amyotrophic Lateral Sclerosis (ALS) (COYA 302). COYA 301 aims to enhance Treg function in AD patients, with data expected in 1H and 2H 2023. COYA 302 focuses on a biologics combination therapy for ALS, with results to be shared in Q1 2023. Coya, a clinical-stage biotech firm, is leveraging Treg-enhancing therapeutics to address neurodegenerative and autoimmune diseases, emphasizing its commitment to further clinical development.
Coya Therapeutics (NASDAQ: COYA) announced a publication highlighting the potential of expanded human Tregs to suppress neuroinflammation and mitigate Alzheimer's Disease (AD) pathology in a preclinical mice model. The study demonstrated that Treg administration decreased amyloid burden and neuroinflammatory markers, supporting the development of Treg-enhancing therapies as a potential strategy for AD and other neurodegenerative disorders. Coya plans to initiate Phase I clinical trials for these therapies in 2023, with interim data expected by Q1 2024.
Coya Therapeutics, Inc. (Nasdaq: COYA), a clinical-stage biotechnology company, has successfully closed its initial public offering (IPO) of 3,050,000 shares and warrants to purchase additional shares, raising approximately $15.25 million. The shares were sold at $5.00 each, with warrants priced at an exercise fee of $7.50. Trading began on December 29, 2022. Proceeds will primarily support preclinical and clinical trials and various corporate purposes. Underwriters hold an option to purchase 290,000 additional shares to cover over-allotments.
Coya Therapeutics, Inc. (Nasdaq: COYA) announced the pricing of its IPO, offering 3,050,000 shares at $5.00 each, along with warrants to purchase 1,525,000 shares. The IPO is expected to yield approximately $15.25 million in gross proceeds. Net proceeds, after expenses, are projected to be about $13.2 million, intended for advancing clinical trials and corporate purposes. The shares will trade on Nasdaq starting December 29, 2022, and the offering is scheduled to close on January 3, 2023. Joint book-runners include Chardan and Newbridge Securities Corporation.